Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Cytosorbents (CTSO) Receivables - Other (2017 - 2026)

Cytosorbents filings provide 9 years of Receivables - Other readings, the most recent being $7.1 million for Q4 2025.

  • On a quarterly basis, Receivables - Other rose 27.23% to $7.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.1 million, a 27.23% increase, with the full-year FY2025 number at $7.1 million, up 27.23% from a year prior.
  • Receivables - Other hit $7.1 million in Q4 2025 for Cytosorbents, up from $6.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $7.1 million in Q4 2025 to a low of $2.8 million in Q1 2021.
  • Median Receivables - Other over the past 5 years was $4.6 million (2023), compared with a mean of $4.7 million.
  • The widest YoY moves for Receivables - Other: up 62.34% in 2021, down 0.13% in 2021.
  • Cytosorbents' Receivables - Other stood at $3.0 million in 2021, then increased by 27.39% to $3.8 million in 2022, then skyrocketed by 38.65% to $5.3 million in 2023, then rose by 5.66% to $5.6 million in 2024, then increased by 27.23% to $7.1 million in 2025.
  • The last three reported values for Receivables - Other were $7.1 million (Q4 2025), $6.0 million (Q3 2025), and $6.6 million (Q2 2025) per Business Quant data.